Better Artificial Intelligence Stock: GSK or Eli Lilly?

Late last year, Open AI's ChatGPT introduced the wider world to the immense power of artificial intelligence (AI). However, pharmaceutical companies have been experimenting with various forms of next-generation AI since the middle of the last decade. These AI systems can help accelerate drug discovery, optimize clinical trials, and improve patient outcomes. This tool opens up new possibilities for creating novel therapies that can improve the lives of millions of patients.

AI is thus poised to radically transform the pharmaceutical industry. Two of the leading players in this field are Eli Lilly (NYSE: LLY) and GSK (NYSE: GSK), both of which have invested heavily in AI technologies and partnerships. But which of these two stocks is a better buy for investors who want to capitalize on the AI revolution in pharma? Here is a brief comparison of their strengths and weaknesses. 

In a recent deal worth $250 million, Chinese AI company XtalPi partnered with Lilly to leverage its cutting-edge AI and robotics technology for drug discovery and development. XtalPi's AI platform can accelerate the identification and optimization of novel drug candidates for various diseases. The specific disease area and the target of the joint project were not revealed by Lilly, but the company expects to initiate clinical trials of the new drug soon. This partnership could potentially transform the way big pharma companies approach drug discovery for unmet medical needs.

Continue reading

Source Fool.com